Teresa Caiazzo
Research Subjects
Teresa Caiazzo has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Hendrik Neubert
Biomedicine Design, Worldwide Research & Development, Pfizer Inc, Andover, USA
2 shared publications Alison P Joyce
Pfizer Inc., BioMedicine Design, One Burtt Road, Andover, MA01810, USA
1 shared publication- Caroline Le Guiner
Nantes Université, CHU Nantes, INSERM, TaRGeT, UMR, Translational Research for Gene Therapy, Nantes, France
1 shared publication Christopher M Shea
Pfizer Inc., BioMedicine Design, One Burtt Road, Andover, MA01810, USA
1 shared publication- Denise M. O’hara
Biomedicine Design, Pfizer Worldwide Research & Development, Andover, MA 01810, USA
1 shared publication - Florence Yong
Biostatistics, Worldwide Research & Development, Pfizer Inc, Cambridge, USA
1 shared publication
Latest Publications
- 8 November 2021
- Published by Taylor & Francis in Bioanalysis
- Vol. 13 (22) , 1659-1669
A Competitive Ligand-Binding Assay to Detect Neutralizing Antibodies to a Bispecific Drug Using a Multiplex Meso Scale Discovery Platform
Background: Monitoring appearance of neutralizing antibodies (NAbs) to multidomain large molecule drugs is a challenging task. Materials & methods: Here, we report development of a competitive liga...
- 8 November 2021
- Published by Taylor & Francis in Bioanalysis
- Vol. 13 (22) , 1659-1669
A Competitive Ligand-Binding Assay to Detect Neutralizing Antibodies to a Bispecific Drug Using a Multiplex Meso Scale Discovery Platform
Background: Monitoring appearance of neutralizing antibodies (NAbs) to multidomain large molecule drugs is a challenging task. Materials & methods: Here, we report development of a competitive liga...
- Open Access
- 5 November 2021
- Published by Springer Nature in Gene Therapy
- Vol. 29 (10-11) , 608-615
Dystrophin and mini-dystrophin quantification by mass spectrometry in skeletal muscle for gene therapy development in Duchenne muscular dystrophy
Duchenne muscular dystrophy (DMD) is a lethal, degenerative muscle disorder caused by mutations in the DMD gene, leading to severe reduction or absence of the protein dystrophin. Gene therapy strategies that aim to increase expression of a functional dystrophin protein (mini-dystrophin) are under investigation. The ability to accurately quantify dystrophin/mini-dystrophin is essential in assessing the level of gene transduction. We demonstrated the validation and application of a novel peptide immunoaffinity liquid chromatography–tandem mass spectrometry (IA-LC-MS/MS) assay. Data showed that dystrophin expression in Becker muscular dystrophy and DMD tissues, normalized against the mean of non-dystrophic control tissues (n = 20), was 4–84.5% (mean 32%, n = 20) and 0.4–24.1% (mean 5%, n = 20), respectively. In a DMD rat model, biceps femoris tissue from dystrophin-deficient rats treated with AAV9.hCK.Hopti-Dys3978.spA, an adeno-associated virus vector containing a mini-dystrophin transgene, showed a dose-dependent increase in mini-dystrophin expression at 6 months post-dose, exceeding wildtype dystrophin levels at high doses. Validation data showed that inter- and intra-assay precision were ≤20% (≤25% at the lower limit of quantification [LLOQ]) and inter- and intra-run relative error was within ±20% (±25% at LLOQ). IA-LC-MS/MS accurately quantifies dystrophin/mini-dystrophin in human and preclinical species with sufficient sensitivity for immediate application in preclinical/clinical trials.
- 5 November 2021
- Published by Springer Nature in Gene Therapy
- Vol. 29 (10-11) , 608-615
Open AccessDystrophin and mini-dystrophin quantification by mass spectrometry in skeletal muscle for gene therapy development in Duchenne muscular dystrophy
Duchenne muscular dystrophy (DMD) is a lethal, degenerative muscle disorder caused by mutations in the DMD gene, leading to severe reduction or absence of the protein dystrophin. Gene therapy strategies that aim to increase expression of a functional dystrophin protein (mini-dystrophin) are under investigation. The ability to accurately quantify dystrophin/mini-dystrophin is essential in assessing the level of gene transduction. We demonstrated the validation and application of a novel peptide immunoaffinity liquid chromatography–tandem mass spectrometry (IA-LC-MS/MS) assay. Data showed that dystrophin expression in Becker muscular dystrophy and DMD tissues, normalized against the mean of non-dystrophic control tissues (n = 20), was 4–84.5% (mean 32%, n = 20) and 0.4–24.1% (mean 5%, n = 20), respectively. In a DMD rat model, biceps femoris tissue from dystrophin-deficient rats treated with AAV9.hCK.Hopti-Dys3978.spA, an adeno-associated virus vector containing a mini-dystrophin transgene, showed a dose-dependent increase in mini-dystrophin expression at 6 months post-dose, exceeding wildtype dystrophin levels at high doses. Validation data showed that inter- and intra-assay precision were ≤20% (≤25% at the lower limit of quantification [LLOQ]) and inter- and intra-run relative error was within ±20% (±25% at LLOQ). IA-LC-MS/MS accurately quantifies dystrophin/mini-dystrophin in human and preclinical species with sufficient sensitivity for immediate application in preclinical/clinical trials.
- 22 April 2021
- Published by Taylor & Francis in Bioanalysis
- Vol. 13 (10) , 807-815
Critical Reagent Characterization and Re-Evaluation to Ensure Long-Term Stability: Two Case Studies
Characterization of critical reagents can mitigate adverse impact to ligand-binding assay performance. We investigated the conjugation conditions of a bispecific protein to SULFO-TAG NHS-Ester™ rut...
- 22 April 2021
- Published by Taylor & Francis in Bioanalysis
- Vol. 13 (10) , 807-815
Critical Reagent Characterization and Re-Evaluation to Ensure Long-Term Stability: Two Case Studies
Characterization of critical reagents can mitigate adverse impact to ligand-binding assay performance. We investigated the conjugation conditions of a bispecific protein to SULFO-TAG NHS-Ester™ rut...
- Open Access
- 15 August 2019
- Published by MDPI AG in Biomolecules
- Vol. 9 (8) , 373
Human FcRn Tissue Expression Profile and Half-Life in PBMCs
System-wide quantitative characterization of human neonatal Fc receptor (FcRn) properties is critical for understanding and predicting human PK (pharmacokinetics) as well as the distribution of mAbs and Fc-fusion proteins using PBPK (physiologically-based pharmacokinetic) modeling. To this end, tissue-specific FcRn expression and half-life are important model inputs. Herein, human FcRn tissue expression was measured by peptide immunoaffinity chromatography coupled with high-resolution mass spectrometry. FcRn concentrations across 14 human tissues ranged from low to 230 pmol per gram of tissue. Furthermore, the FcRn half-life was determined to be 11.1 h from a human stable isotope labelled leucine pulse labeling experiment. The spatial and temporal quantitative human FcRn data now promise to enable a refined PBPK model with improved accuracy of human PK predictions for Fc-containing biotherapeutics.
- 15 August 2019
- Published by MDPI AG in Biomolecules
- Vol. 9 (8) , 373
Open AccessHuman FcRn Tissue Expression Profile and Half-Life in PBMCs
System-wide quantitative characterization of human neonatal Fc receptor (FcRn) properties is critical for understanding and predicting human PK (pharmacokinetics) as well as the distribution of mAbs and Fc-fusion proteins using PBPK (physiologically-based pharmacokinetic) modeling. To this end, tissue-specific FcRn expression and half-life are important model inputs. Herein, human FcRn tissue expression was measured by peptide immunoaffinity chromatography coupled with high-resolution mass spectrometry. FcRn concentrations across 14 human tissues ranged from low to 230 pmol per gram of tissue. Furthermore, the FcRn half-life was determined to be 11.1 h from a human stable isotope labelled leucine pulse labeling experiment. The spatial and temporal quantitative human FcRn data now promise to enable a refined PBPK model with improved accuracy of human PK predictions for Fc-containing biotherapeutics.